title: Effect of substance P on superoxide anion and IL-8 production by human PMNL.
abstract: The neuropeptide substance P (SP), a main mediator of neurogenic inflammation, has been shown to have direct and modulatory effects on functional responses of polymorphonuclear leucocytes (PMNL). In this study, we further investigated the effects exerted by SP on human PMNL functions. Pretreatment of PMNL with SP resulted in an increase of superoxide anion (O2-) production in response to formyl-methionyl-leucyl-phenylalanine (FMLP), concanavalin A (Con A) and opsonized zymosan (STZ). In contrast, the O2- production induced by tumour necrosis factor (TNF) was strongly inhibited by pretreatment with SP. Both enhancement and inhibition of O2- response were exerted by SP in a dose-dependent manner and at concentrations which did not directly stimulate O2- production. These effects were rapid in onset, and occurred after 5 min of preincubation of cells with the neuropeptide. At concentrations that modulated O2- production by PMNL, SP also directly stimulated release of the chemotactic cytokine interleukin-8 (IL-8). Induction of IL-8 release required a longer incubation time (1 hr) with SP and was preceded by an increase of IL-8 mRNA steady-state levels. Furthermore, as well as directly stimulating IL-8 production, SP was also able to enhance the IL-8 release induced by other stimuli such as FMLP and TNF. The results of this study indicate that, in addition to the rapid and differential modulation of O2- production, SP also induces long-term changes such as IL-8 synthesis and release, and can thus amplify the process of PMNL recruitment to the inflammatory site.
authors.affiliation: Institute of General Pathology, University of Verona, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Serra
authors.forename: F
authors.initials: F
authors.lastname: Calzetti
authors.forename: M
authors.initials: M
authors.lastname: Ceska
authors.forename: M A
authors.initials: MA
authors.lastname: Cassatella
mesh_terms: D003208:Concanavalin A / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D016209:Interleukin-8 / Q000097:blood* / Q000235:genetics; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D013373:Substance P / Q000494:pharmacology*; D013481:Superoxides / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
chemical_list: D016209:Interleukin-8; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; D013481:Superoxides; D013373:Substance P; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015054:Zymosan